GENIUS METALS INC (GENI.CA) Fundamental Analysis & Valuation

TSX-V:GENI • CA37230M1059

Current stock price

0.085 CAD
0 (0%)
Last:

This GENI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GENI.CA Profitability Analysis

1.1 Basic Checks

  • In the past year GENI has reported negative net income.
  • GENI had a negative operating cash flow in the past year.
  • In the past 5 years GENI always reported negative net income.
  • GENI had a negative operating cash flow in each of the past 5 years.
GENI.CA Yearly Net Income VS EBIT VS OCF VS FCFGENI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -1M -2M -3M

1.2 Ratios

Industry RankSector Rank
ROA -14.95%
ROE -16.13%
ROIC N/A
ROA(3y)-18.17%
ROA(5y)-19.95%
ROE(3y)-19.49%
ROE(5y)-23.38%
ROIC(3y)N/A
ROIC(5y)N/A
GENI.CA Yearly ROA, ROE, ROICGENI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • GENI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENI.CA Yearly Profit, Operating, Gross MarginsGENI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. GENI.CA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, GENI has more shares outstanding
  • Compared to 5 years ago, GENI has more shares outstanding
  • GENI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GENI.CA Yearly Shares OutstandingGENI.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
GENI.CA Yearly Total Debt VS Total AssetsGENI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • GENI has an Altman-Z score of 10.15. This indicates that GENI is financially healthy and has little risk of bankruptcy at the moment.
  • A Debt/Equity ratio of 0.01 indicates that GENI is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 10.15
ROIC/WACCN/A
WACCN/A
GENI.CA Yearly LT Debt VS Equity VS FCFGENI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M 6M

2.3 Liquidity

  • A Current Ratio of 1.12 indicates that GENI should not have too much problems paying its short term obligations.
  • GENI has a Quick Ratio of 1.12. This is a normal value and indicates that GENI is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.12
GENI.CA Yearly Current Assets VS Current LiabilitesGENI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500K 1M 1.5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. GENI.CA Growth Analysis

3.1 Past

  • GENI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.24%, which is quite impressive.
EPS 1Y (TTM)32.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. GENI.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GENI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GENI.CA Price Earnings VS Forward Price EarningsGENI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GENI.CA Per share dataGENI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GENI.CA Dividend Analysis

5.1 Amount

  • No dividends for GENI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GENI.CA Fundamentals: All Metrics, Ratios and Statistics

GENIUS METALS INC

TSX-V:GENI (3/11/2025, 7:00:00 PM)

0.085

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners7.23%
Ins Owner ChangeN/A
Market Cap9.85M
Revenue(TTM)N/A
Net Income(TTM)-1.01M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.58
P/tB 1.58
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.95%
ROE -16.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.17%
ROA(5y)-19.95%
ROE(3y)-19.49%
ROE(5y)-23.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14792.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.12
Altman-Z 10.15
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)65287%
Cap/Depr(5y)58682.2%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.88%
OCF growth 3YN/A
OCF growth 5YN/A

GENIUS METALS INC / GENI.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GENIUS METALS INC (GENI.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to GENI.CA.


What is the valuation status for GENI stock?

ChartMill assigns a valuation rating of 0 / 10 to GENIUS METALS INC (GENI.CA). This can be considered as Overvalued.


Can you provide the profitability details for GENIUS METALS INC?

GENIUS METALS INC (GENI.CA) has a profitability rating of 0 / 10.


How financially healthy is GENIUS METALS INC?

The financial health rating of GENIUS METALS INC (GENI.CA) is 3 / 10.